A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513356-15-00

Acronym

101380003SA

Enrollment

291

Registered

2024-11-20

Start date

2024-12-30

Completion date

Unknown

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Blepharoptosis

Brief summary

Change from baseline in MRD1 on Day 14

Detailed description

PRO: PGIC on Day 14

Interventions

DRUGSTN1013800

DRUGPlacebo to OXYMETAZOLINE HYDROCHLORIDE (Vehicle)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in MRD1 on Day 14	—

Secondary

Measure	Time frame
PRO: PGIC on Day 14	—

Countries

Czechia, France, Germany, Hungary, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026